

Date: August 08, 2025

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Intimation of Schedule of Earnings Conference Call under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an Earnings Conference Call to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025, is scheduled for **Thursday, August 14, 2025 at 12:00 PM IST/ 14:30 SGT/HKT**.

The details pertaining to the said call are enclosed herewith and the same will also be available on the Company's website at <https://www.anthembio.com/investor.html>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Private Limited)

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Corporate Access AEJ
Striving for Excellence

INVITATION
Anthem Biosciences Ltd (ANTHEM) Q1FY26 Earnings Call
August 14, Thursday
12.00 IST
14.30 SGT/HKT

We are pleased to host **Anthem Biosciences Ltd (ANTHEM) Q1FY26 Earnings Call** on August 14, Thursday at 12.00 IST with below details.

Event Information

Date & Time	August 14, Thursday 12:00 IST/14:30 SGT/HKT
Topic	Anthem Biosciences Ltd (ANTHEM) Q1FY26 Earnings Call
Company Description	Anthem Biosciences Limited, founded in 2006, is an integrated CRDMO (contract research, development and manufacturing organization) with capabilities across small and large molecules (biologics). The Company offers services across the product lifecycle, including drug discovery, development, and commercial manufacturing services for biotech and large pharmaceutical industries. Anthem Biosciences serves customers globally and has technical capabilities across various product segments such as ADCs, RNAi, peptides and oligonucleotides. The company was listed on NSE and BSE on 21 July 2025
Mgmt Reps	Mr. Ajay Bhardwaj, Managing Director and Chief Executive Officer Mr. Gawir Baig, Chief Financial Officer
Moderators	Saion Mukherjee, Managing Director & Head of Equity Research India, Nomura Amlan Jyoti Das, Associate - Strategy & Healthcare, Equity Research, India, Nomura
Chorus	Diamond Pass link: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7944284&linkSecurityString=3bc80b5f00 Universal Dial-In +91 22 6280 1548 +91 22 7115 8376 International Dial in Singapore 8001012045 HK 800964448 Japan 00531161110 UK 08081011573

Nomura Analyst

	Saion Mukherjee Managing Director & Head of Equity Research India, Nomura		Amlan Jyoti Das Associate, Strategy & Healthcare, Equity Research, India, Nomura
---	--	---	---

Nomura Corporate Access Enquiries

Linda Ngatemo Corporate & Investor Access +65 6433 6515 linda.ngatemo@nomura.com	Deanna Choo Corporate & Investor Access +65 6433 6493 deanna.choo@nomura.com	Juliet D'mello Nomura Securities India +91 22 403 74307 juliet.dmello@nomura.com
--	--	--

Connecting Markets East & West

www.nomura.com

Copyright © 2025 Nomura Holdings, Inc. All rights reserved.

"This event is being organized by Nomura for its clients for their general information and education. This event does not constitute an offer or a solicitation of an offer to buy or sell financial products or services to you. Nomura may invite a third-party guest speaker but Nomura has not sought to independently verify the views or information that you may receive from such speaker or the institution he/she represents during the event and makes no representations or warranties as to the accuracy, completeness or reliability of such views or information. Nomura takes no responsibility for that information that is provided or used at any time thereafter. Please note that this event may be recorded. Where requested by a relevant listed issuer or to meet regulatory requirements, the recordings of such event, transcripts of the call, and/or other relevant materials may be provided to the local exchange or regulator or to the listed issuer and be published on the listed issuer's website.

Nomura will process your personal data for purposes in connection with the event and for future events, such as the general administration and organisation of the event or to invite you to future events that you may be interested in. Your personal data may be shared with third parties involved in the event, such as a relevant listed issuer or local exchange or regulator for purposes mentioned above; the venue provider and other third parties who are involved in the administration of the event; and/or Nomura group companies, in accordance with the applicable Nomura Group Privacy Policy. Further information about the Nomura Group privacy policies can be found [here](#). Where requested by a listed issuer third-party guest speaker, we may share your personal data with them for their records and/or for them to connect with the organisation you represent to enhance investor relations. Nomura is not responsible for and does not control the relevant listed issuer's use of your personal data, which will be in accordance with their own privacy policies. If you do not wish for your personal data to be shared in the above manner, you may choose not to register for the event. By registering for the event, you acknowledge and agree to the terms above and the Nomura Group Privacy Policy"